See more : Sanrin Co., Ltd. (7486.T) Income Statement Analysis – Financial Results
Complete financial analysis of Emmaus Life Sciences, Inc. (EMMA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Emmaus Life Sciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Eargo, Inc. (EAR) Income Statement Analysis – Financial Results
- Omeros Corporation (OMER) Income Statement Analysis – Financial Results
- Bangi Inc. (BNGI) Income Statement Analysis – Financial Results
- Brown-Forman Corporation (BF-A) Income Statement Analysis – Financial Results
- New Asia Holdings, Inc. (NAHD) Income Statement Analysis – Financial Results
Emmaus Life Sciences, Inc. (EMMA)
About Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 29.60M | 18.39M | 20.61M | 23.17M | 22.75M | 1.32M | 128.50K | 85.10K | 100.10K | 135.10K | 130.90K | 115.00K | 745.90K | 638.50K | 700.10K | 773.50K | 238.40K | 0.00 | 0.00 | 0.00 | 6.80K | 7.89K | 8.28K | 14.26K | 20.00K |
| Cost of Revenue | 1.34M | 2.59M | 3.31M | 2.25M | 1.09M | 827.40K | 53.50K | 5.50K | 4.90K | 73.00K | 142.60K | 132.00K | 147.10K | 135.10K | 131.60K | 163.20K | 166.20K | 0.00 | 0.00 | 0.00 | 885.00 | 1.21K | 1.15K | 5.78K | 10.00K |
| Gross Profit | 28.26M | 15.80M | 17.30M | 20.92M | 21.66M | 488.10K | 75.00K | 79.60K | 95.20K | 62.10K | -11.70K | -17.00K | 598.80K | 503.40K | 568.50K | 610.30K | 72.20K | 0.00 | 0.00 | 0.00 | 5.91K | 6.68K | 7.13K | 8.48K | 10.00K |
| Gross Profit Ratio | 95.47% | 85.93% | 83.93% | 90.30% | 95.19% | 37.10% | 58.37% | 93.54% | 95.10% | 45.97% | -8.94% | -14.78% | 80.28% | 78.84% | 81.20% | 78.90% | 30.29% | 0.00% | 0.00% | 0.00% | 86.98% | 84.66% | 86.15% | 59.49% | 50.00% |
| Research & Development | 1.19M | 1.73M | 4.11M | 2.41M | 2.18M | 1.38M | 1.36M | 794.20K | 783.80K | 1.45M | 1.29M | 853.70K | 924.80K | 1.12M | 2.14M | 2.10M | 1.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 14.89M | 13.17M | 13.44M | 13.68M | 17.01M | 7.36M | 4.42M | 2.50M | 1.62M | 2.03M | 2.54M | 2.94M | 4.27M | 5.02M | 3.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.40K | 15.55K | 20.00K |
| Selling & Marketing | 8.64M | 7.49M | 5.88M | 4.87M | 6.98M | 1.99M | 1.40M | 550.50K | 347.90K | 390.20K | 366.30K | 997.10K | 1.23M | 870.90K | 915.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.53M | 20.66M | 19.32M | 18.54M | 23.99M | 9.36M | 5.82M | 3.05M | 1.97M | 2.42M | 2.90M | 3.94M | 5.50M | 5.89M | 4.80M | 3.99M | 1.90M | 416.21K | 28.58K | 261.09K | 144.54K | 17.06K | 16.40K | 15.55K | 20.00K |
| Other Expenses | 0.00 | -3.98M | 0.00 | 0.00 | -3.34M | 0.00 | 0.00 | 306.70K | 0.00 | 44.10K | 0.00 | 0.00 | 381.70K | 0.00 | 320.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 24.72M | 22.39M | 23.43M | 20.95M | 26.17M | 10.73M | 7.18M | 3.85M | 2.75M | 3.88M | 4.19M | 4.79M | 6.43M | 7.01M | 6.94M | 6.08M | 3.34M | 416.21K | 28.58K | 261.09K | 144.54K | 17.06K | 16.40K | 15.55K | 20.00K |
| Cost & Expenses | 26.06M | 24.98M | 26.74M | 23.20M | 27.26M | 11.56M | 7.23M | 3.85M | 2.76M | 3.95M | 4.33M | 4.92M | 6.58M | 7.14M | 7.07M | 6.25M | 3.51M | 416.21K | 28.58K | 261.09K | 145.43K | 18.27K | 17.55K | 21.33K | 30.00K |
| Interest Income | 681.00K | 680.00K | 761.00K | 2.30M | 232.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.38M | 0.00 | 0.00 | 99.50K | 104.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.00 | 11.00 | 0.00 |
| Interest Expense | 7.38M | 5.01M | 3.10M | 5.99M | 27.39M | 86.30K | 6.60K | 2.72M | 257.40K | 0.00 | 1.29M | 0.00 | 7.57M | 1.67M | 2.14M | 0.00 | 115.60K | 18.53K | 30.57K | 4.51K | 725.00 | 458.00 | 203.00 | 0.00 | -10.00K |
| Depreciation & Amortization | 32.00K | 53.00K | 59.00K | 60.00K | 73.00K | 113.10K | 48.70K | 7.20K | 7.60K | 10.30K | 13.00K | 18.80K | 11.90K | 9.40K | 9.10K | 6.30K | 19.90K | 225.00K | 39.33K | 0.00 | 96.00 | 0.00 | 65.00 | 231.00 | -20.00K |
| EBITDA | 3.57M | -5.50M | -12.76M | 28.00K | -26.98M | -10.13M | -7.05M | -3.19M | -3.12M | -2.63M | -4.19M | -4.79M | -1.29M | -7.80M | -6.67M | -5.47M | -3.25M | 553.80K | -1.09M | -261.09K | -138.63K | -10.38K | -9.20K | -6.84K | -30.00K |
| EBITDA Ratio | 12.07% | -35.81% | -39.02% | 0.07% | -36.01% | -769.82% | -5,490.19% | -4,726.56% | -2,179.42% | -3,654.92% | 875.63% | -4,162.70% | -779.93% | -812.51% | -850.25% | -706.89% | -1,407.97% | 0.00% | 0.00% | 0.00% | -2,041.27% | -131.43% | -111.20% | -47.98% | -150.00% |
| Operating Income | 3.54M | -6.59M | -6.13M | -43.00K | -4.51M | -10.24M | -7.10M | -3.77M | -2.66M | -3.82M | -4.20M | -4.81M | -5.83M | -6.51M | -6.69M | -5.47M | -3.27M | -416.21K | -28.58K | -261.09K | -138.63K | -10.38K | -9.27K | -7.07K | -10.00K |
| Operating Income Ratio | 11.96% | -35.81% | -29.73% | -0.19% | -19.83% | -778.78% | -5,528.09% | -4,426.32% | -2,653.75% | -2,825.17% | -3,209.01% | -4,179.04% | -781.53% | -1,018.79% | -955.88% | -707.71% | -1,371.48% | 0.00% | 0.00% | 0.00% | -2,039.86% | -131.43% | -111.99% | -49.60% | -50.00% |
| Total Other Income/Expenses | -7.33M | -3.98M | -9.79M | 1.01M | -50.17M | -317.80K | -6.60K | -2.17M | -724.60K | 1.16M | -6.69M | 1.89M | -2.50M | -1.67M | -1.82M | 104.00K | -8.70K | -18.53K | 8.76K | -4.51K | -629.00 | -458.00 | -197.00 | 11.00 | -10.00K |
| Income Before Tax | -3.79M | -10.63M | -15.92M | 719.00K | -54.68M | -10.33M | -7.11M | -5.94M | -3.38M | -2.65M | -10.89M | -2.91M | -8.87M | -8.17M | -8.52M | -5.37M | -3.28M | -434.74K | -19.82K | -265.60K | -139.26K | -10.83K | -9.47K | -7.06K | -20.00K |
| Income Before Tax Ratio | -12.81% | -57.78% | -77.25% | 3.10% | -240.32% | -785.34% | -5,533.23% | -6,978.73% | -3,377.62% | -1,965.14% | -8,317.19% | -2,534.26% | -1,188.54% | -1,280.06% | -1,216.25% | -694.26% | -1,375.13% | 0.00% | 0.00% | 0.00% | -2,049.12% | -137.23% | -114.37% | -49.53% | -100.00% |
| Income Tax Expense | -59.00K | 60.00K | 25.00K | -381.00K | 164.00K | 1.90K | 2.60K | 2.00K | 5.00K | 5.20K | 800.00 | 1.90K | 1.30K | 800.00 | 7.20K | 1.40K | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 20.00K |
| Net Income | -3.73M | -10.69M | -15.95M | 1.35M | -54.84M | -9.60M | -7.11M | -5.94M | -3.38M | -2.66M | -10.91M | -3.41M | -8.87M | -8.17M | -8.52M | -5.37M | -3.28M | -435.54K | -20.62K | -266.40K | -140.06K | -11.63K | -10.27K | -7.86K | -40.00K |
| Net Income Ratio | -12.61% | -58.10% | -77.37% | 5.84% | -241.04% | -729.66% | -5,535.25% | -6,981.08% | -3,376.02% | -1,970.98% | -8,332.62% | -2,962.43% | -1,188.71% | -1,280.19% | -1,217.28% | -694.44% | -1,375.46% | 0.00% | 0.00% | 0.00% | -2,060.89% | -147.37% | -124.03% | -55.14% | -200.00% |
| EPS | -0.07 | -0.22 | -0.32 | 0.03 | -1.30 | -11.08 | -15.15 | -55.54 | -39.83 | -32.17 | -172.68 | -2.14K | -5.69K | -5.63K | -7.35K | -7.65K | -2.11K | -279.91 | -13.25 | -171.21 | -90.01 | -7.48 | -6.60 | -5.05 | 0.00 |
| EPS Diluted | -0.07 | -0.22 | -0.32 | 0.03 | -1.30 | -11.08 | -15.15 | -55.54 | -39.83 | -32.17 | -172.68 | -2.14K | -5.69K | -5.63K | -7.35K | -7.65K | -2.11K | -279.91 | -13.25 | -171.21 | -90.01 | -7.48 | -6.60 | -5.05 | 0.00 |
| Weighted Avg Shares Out | 53.11M | 49.44M | 49.25M | 48.90M | 42.26M | 866.59K | 469.57K | 106.97K | 84.84K | 82.77K | 63.17K | 1.60K | 1.56K | 1.45K | 1.16K | 702.00 | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 49.31M |
| Weighted Avg Shares Out (Dil) | 53.11M | 49.44M | 49.25M | 48.90M | 42.26M | 866.60K | 469.57K | 106.97K | 84.84K | 82.77K | 63.17K | 1.60K | 1.56K | 1.45K | 1.16K | 702.00 | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 49.31M |
Emmaus Life Sciences Reports Improved Quarterly Financial Results
TORRANCE, Calif. , Nov. 19, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. ( OTCQB : EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as...
Emmaus Life Sciences Reports Quarterly Financial Results
TORRANCE, Calif. , Sept. 10, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC Markets: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of...
Emmaus Life Sciences Announces Willis C. Lee as Chief Executive Officer
TORRANCE, Calif. , July 23, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCMarkets: EMMA), a leader in sickle cell disease treatment, announced that Willis C.
Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program
TORRANCE, Calif. , July 12, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced receiving the coveted "No Action Indicated" classification following a routine inspection by...
Emmaus Life Sciences Reports 2023 Financial Results
TORRANCE, Calif. , July 3, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and...
Emmaus Life Sciences Reports Delayed Filing of Annual Report
TORRANCE, Calif. , April 15, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, reported today that the filing of its Annual Report on Form 10-K for...
Emmaus Life Sciences obtains marketing authorization for sickle cell disease teatment in Puerto Rico
Emmaus Life Sciences Inc (OTCQX:EMMA) said it had obtained marketing authorization from the Puerto Rico Department of Health for its sickle cell disease (SCD) treatment, Endari, an L-glutamine oral powder. This approval enhances accessibility to Endari for SCD patients in...
Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico
TORRANCE, Calif. , Feb. 2, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease (SCD) treatment, today announced that it has received marketing authorization from the Puerto Rico Department of Health for Endari® (L-glutamine oral...
Emmaus Life Sciences sees increased Endari sales in MENA and US during 3Q
Emmaus Life Sciences Inc (OTCQX:EMMA) reported a year-over-year increase in third quarter revenue driven by increased sales of its sickle cell therapy Endari in the Middle East North Africa (MENA) region and the United States. The commercial-stage biopharma company reported...
Emmaus Life Sciences Reports Q3 2023 Financial Results
TORRANCE, Calif. , Nov. 14, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for...
Source: https://incomestatements.info
Category: Stock Reports